ArticleDermatology and therapy2026
Long-Term Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A Real-World, Retrospective Study.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Atopic Dermatitis Beyond the Skin Barrier: Precision Medicine Approaches to Immunological Profiling and Therapeutic Innovation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAbrocitinib constitutes one of the most effective therapeutic agents for the treatment of atopic dermatitis (AD). However, real-world data validating its effectiveness outside randomized controlled trials remain limited and are primarily based on short-term follow-up studies. Herein, we aimed to summarize our 2-year experience with abrocitinib for AD.
methodsIn this retrospective cohort study, all patients with moderate-to-severe AD who received abrocitinib were included. The following physician- and patient-reported outcomes were collected at baseline and weeks 4, 12, 24, 52, and week 104: Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), Investigator Global Assessment (IGA), Worst Pruritus Numeric Rating Scale (WP-NRS), Dermatology Life Quality Index (DLQI), and a stringent combined outcome (EASI90 and WP-NRS 0/1). Long-term safety was evaluated using clinical and laboratory data and patient-reported adverse events (AEs).
resultsA total of 23 patients [15 male patients/8 female patients; mean (SD) age 29.1 (11.5) years] were included. The mean (SD) EASI score significantly decreased from baseline to week 104 [from 25.0 (11.2) to 3.9 (7.7); p < 0.01], while mean (SD) SCORAD decreased from 67.2 (14.1) to 9.7 (19.3) (p < 0.01). Corresponding EASI75, EASI90, EASI100, and IGA 0/1 responses were achieved by 19 (83%), 13 (57%), 12 (52%), and 14 (61%) patients, respectively. Regarding patient-reported outcomes, QoL and itch severity improved significantly up to week 104, with 61% and 83% of patients achieving DLQI < 2 and WP-NRS 0/1, respectively. Three patients (13%) discontinued abrocitinib due to AEs, with the remaining AEs being mild in severity.
conclusionThis real-world study supports clinical trial findings on the high effectiveness of abrocitinib in the management of AD. Moreover, it confirms that abrocitinib is generally well tolerated and can lead to early and sustained improvement in pruritus and overall QoL. Despite the small sample size, the results of the present real-world study seem to align with previous data on the effectiveness of abrocitinib also in the long-term management of AD, with an acceptable safety profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.